Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1325 of 2026 entries
View as:

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT00048074 Org: User:
Start: 06/30/02 End: 05/31/05 Due: 05/31/06

Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT00666016 Org: User:
Start: 04/30/08 End: 04/30/09 Due: 04/30/10

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01188317 Org: User:
Start: 06/30/10 End: 09/30/11 Due: 09/30/12

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Phase: N/A Priority: Normal
NCT ID: NCT01555762 Org: User:
Start: 03/05/12 End: 07/20/16 Due: 07/20/17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02541604 Org: User:
Start: 11/30/15 End: 06/06/19 Due: 06/06/20

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Phase: N/A Priority: Normal
NCT ID: NCT01715909 Org: User:
Start: 01/22/14 End: 06/17/18 Due: 06/17/19

A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting

Phase: N/A Priority: Normal
NCT ID: NCT01664104 Org: User:
Start: 06/30/12 End: 12/31/13 Due: 12/31/14

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.

Phase: N/A Priority: Normal
NCT ID: NCT00420472 Org: User:
Start: 03/31/07 End: - Due: -

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Phase: N/A Priority: Normal
NCT ID: NCT01353859 Org: User:
Start: 03/31/11 End: 07/31/12 Due: 07/31/13

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Phase: N/A Priority: Normal
NCT ID: NCT02104648 Org: User:
Start: 04/30/14 End: 08/31/14 Due: 08/31/15

Observational Study of MIRCERA in Users of Self-Application and Multidose Systems

Phase: N/A Priority: Normal
NCT ID: NCT02540213 Org: User:
Start: 01/31/09 End: 11/30/10 Due: 11/30/11

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05861986 Org: User:
Start: 05/30/24 End: 03/31/28 Due: 03/31/29

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05269004 Org: User:
Start: 05/03/22 End: 12/31/29 Due: 12/31/30

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03424005 Org: User:
Start: 03/30/18 End: 05/03/28 Due: 05/03/29

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03178552 Org: User:
Start: 09/22/17 End: 08/03/28 Due: 08/03/29

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Phase: N/A Priority: Normal
NCT ID: NCT05562947 Org: User:
Start: 06/17/24 End: 05/07/29 Due: 05/07/30

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00281918 Org: User:
Start: 07/31/03 End: 10/31/11 Due: 10/31/12

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Phase: N/A Priority: Normal
NCT ID: NCT01810393 Org: User:
Start: 06/11/13 End: 07/17/19 Due: 07/17/20

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT00100984 Org: User:
Start: 07/21/04 End: 07/16/05 Due: 07/16/06

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT02393898 Org: User:
Start: 04/23/15 End: 06/14/19 Due: 06/14/20

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01981850 Org: User:
Start: 10/01/13 End: 07/10/20 Due: 07/10/21

A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01365403 Org: User:
Start: 04/30/11 End: 07/31/11 Due: 07/31/12

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT03762681 Org: User:
Start: 12/14/18 End: 04/06/20 Due: 04/06/21

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03333655 Org: User:
Start: 02/16/18 End: 08/04/22 Due: 08/04/23

A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Phase: N/A Priority: Normal
NCT ID: NCT02040935 Org: User:
Start: 02/21/14 End: 09/14/18 Due: 09/14/19